Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses

Denarda Dangaj1, Nathalie Scholler

  • 1Department of Oncology; Ludwig Cancer Research Center; University of Lausanne; Lausanne, Switzerland.

Oncoimmunology
|October 2, 2013
PubMed

B7-H4 inhibits T-cell activation and is widely expressed by solid neoplasms. We have recently demonstrated that the expression of B7-H4 on the surface of malignant cells in vivo is inducible, and that novel anti-B7-H4 recombinant antibodies can reverse the inhibition of tumor-specific T cells. Thus, antibodies targeting the B7-H4 pathways may extend the survival of cancer patients by restoring T cell-mediated antitumor responses.

Related Concept Videos